MarketInOut Stock Screener Log In | Sign Up

Filana Therapeutics Inc

NASDAQ • Healthcare • Biotechnology • Quote as of 10/30/2026
Filana Therapeutics Inc stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization31.52 mln
Float46.92 mln
Earnings Date11/11/2026

Piotroski F-Score

4 / 9
Borderline

Relative Strength

23 / 100
Significantly lagging

ROE

-56.27
Deeply negative

ROA

-35.49
Deeply negative

Business Description

Founded in 1998 and headquartered in Austin, Texas, Filana Therapeutics Inc. is a medical research company working to fight brain-wasting diseases. Its most advanced treatment, simufilam, is currently in a Phase 3 trial for Alzheimer's disease, while a separate early-stage tool called SavaDx aims to identify the condition using just a small blood sample. The company was previously called Cassava Sciences Inc. before adopting its current name in March 2026.

Key Fundamentals

EPS-0.87
ROE-56.27
ROIC-162
ROA-35.49
EBITDA, mln-41.17
EV / EBITDA1.25
EV / EBIT1.21

Quote Details

Last 0.622
Change -0.036 (-5.47%)
Open 0.6585
Volume 214,118
Turnover 133,181
Average Volume 446,782

Financial Ratios

Leverage Ratio1.63
Current Ratio2.09
Price / Book0.49
Price / Tangible Book0.49
PEG Ratio1.62

Financial Strength

Piotroski F-Score 4 / 9
Short Ratio1.10
Short % of Float11.85

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week -2.12% 38 / 100   
1 Month -35.54% 8 / 100   
2 Months -30.92% 19 / 100   
6 Months -58.81% 10 / 100   



Disclaimer - Privacy Policy - Terms of Service - Cookies - FAQ - Affiliates - Blog